Francesco Cappelli
YOU?
Author Swipe
View article: Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy: from Pathophysiology To Real World Data
Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy: from Pathophysiology To Real World Data Open
Purpose of Review This review aims to provide a comprehensive overview of mavacamten in the management of obstructive hypertrophic cardiomyopathy (oHCM), from its molecular mechanism of action to clinical trial outcomes and real-world appl…
View article: Clinical phenotype and prognosis of real‐world patients with wild‐type transthyretin amyloid cardiomyopathy treated with tafamidis
Clinical phenotype and prognosis of real‐world patients with wild‐type transthyretin amyloid cardiomyopathy treated with tafamidis Open
Aims Tafamidis reshaped the treatment paradigm in transthyretin amyloid cardiomyopathy (ATTR‐CM) based on a phase‐3 randomized controlled trial, but real‐world data on its use remain limited. This study aimed to assess in a large, contempo…
View article: Inflammation and genetics in myo‐pericardial diseases: Insights from the Italian Study Group on Cardiomyopathies and Pericardial Diseases
Inflammation and genetics in myo‐pericardial diseases: Insights from the Italian Study Group on Cardiomyopathies and Pericardial Diseases Open
In the past decade, advancements in knowledge on the immune system have partially unveiled the complex interplay between the heart and the immune system. This new branch of cardiology is now called cardio‐immunology. It encompasses differe…
View article: Cardiac Resynchronization Therapy, Remodeling, and Outcome in Patients With Amyloid Transthyretin Cardiomyopathy
Cardiac Resynchronization Therapy, Remodeling, and Outcome in Patients With Amyloid Transthyretin Cardiomyopathy Open
Background Transthyretin amyloid cardiomyopathy (ATTR‐CM) has a specific pathophysiology, with myocardial stiffening and systolic dysfunction only in advanced stages. We aimed to investigate the response to cardiac resynchronization therap…
View article: Evolution of cardiac damage staged with echocardiography in Fabry disease
Evolution of cardiac damage staged with echocardiography in Fabry disease Open
Background Fabry disease (FD) can be classified in 4 stages, based on the extent of cardiac damage assessed with echocardiography. This staging is strongly associated with prognosis, with a doubled risk increase of cardiovascular events fo…
View article: Sex-specific prognostic thresholds of left ventricular hypertrophy in Fabry disease
Sex-specific prognostic thresholds of left ventricular hypertrophy in Fabry disease Open
Background Left ventricular hypertrophy (LVH) is one of the main prognostic factors in Fabry disease (FD). Despite the known impact of sex on the phenotypic expression of the disease, a "fixed" threshold of left ventricular maximal wall th…
View article: Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The <scp>HELIOS</scp> ‐B trial
Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The <span>HELIOS</span> ‐B trial Open
Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a progressive condition primarily affecting older adults, who are at increased risk of morbidity and mortality. In HELIOS‐B, vutrisiran reduced all‐cause mortality and recurrent cardio…
View article: Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR‐CM
Nuclear imaging and echocardiographic findings in hypertrophic cardiomyopathy with and without ATTR‐CM Open
Aims Patients with transthyretin amyloid cardiomyopathy (ATTR‐CM) often experience delayed diagnosis, which may detrimentally impact clinical outcomes. This study aimed to assess the frequency of use of planar scintigraphy with and without…
View article: Sex-specific prognostic thresholds of left ventricular hypertrophy in fabry disease
Sex-specific prognostic thresholds of left ventricular hypertrophy in fabry disease Open
Aims Left ventricular hypertrophy (LVH) is one of the main prognostic factors in Fabry disease (FD). Despite the known impact of sex on the phenotypic expression of the disease, a ‘fixed’ threshold of left ventricular maximal wall thicknes…
View article: Free-space time-bin encoded quantum key distribution from near- to mid-infrared wavelengths
Free-space time-bin encoded quantum key distribution from near- to mid-infrared wavelengths Open
Quantum technologies play a central role in establishing new ways of quantum-secured communication. We investigate Free-Space Quantum Communication and explore the advantage of implementing Quantum Key Distribution (QKD) with weak coherent…
View article: Characteristics of patients with suspected cardiac amyloidosis in Tuscany and Umbria: Insights from the cardiac amyloidosis RegistRY (CARRY)
Characteristics of patients with suspected cardiac amyloidosis in Tuscany and Umbria: Insights from the cardiac amyloidosis RegistRY (CARRY) Open
View article: Outcome and Disease Progression in NYHA Functional Class I and II Patients With Wild-Type Transthyretin Cardiomyopathy Treated With Tafamidis
Outcome and Disease Progression in NYHA Functional Class I and II Patients With Wild-Type Transthyretin Cardiomyopathy Treated With Tafamidis Open
v
View article: Correction: Frailty and caregiver relationship quality in older patients diagnosed with transthyretin cardiac amyloidosis
Correction: Frailty and caregiver relationship quality in older patients diagnosed with transthyretin cardiac amyloidosis Open
View article: Prognostic Value of Malnutrition, Frailty, and Physical Performance in Transthyretin Cardiac Amyloidosis: Insights From a Prospective Multicenter Cohort Study
Prognostic Value of Malnutrition, Frailty, and Physical Performance in Transthyretin Cardiac Amyloidosis: Insights From a Prospective Multicenter Cohort Study Open
BACKGROUND: The prevalence of transthyretin cardiac amyloidosis among older adults (often octogenarians) is increasing. We aimed to determine whether age and geriatric syndromes bear any impact on the management and outcomes in transthyret…
View article: Anxiety and depression in cardiac amyloidosis: a systematic review
Anxiety and depression in cardiac amyloidosis: a systematic review Open
Objectives Cardiac amyloidosis (CA) is a rare and underdiagnosed disease associated with a high mortality rate. Although, in the last decade, there has been increasing attention in the literature to the relationship between CA and psycholo…
View article: Revised renal stratification and progression models for predicting long-term renal outcomes in immunoglobulin light chain amyloidosis
Revised renal stratification and progression models for predicting long-term renal outcomes in immunoglobulin light chain amyloidosis Open
Renal prognosis in light-chain amyloidosis (AL) is determined by categorizing patients into three renal stages at diagnosis and assessing Renal Response or Renal Progression following chemotherapy after 6 months. We evaluated, in a test (N…
View article: Response to correspondence on ‘Change in prevalence of ATTR variants in Italy’
Response to correspondence on ‘Change in prevalence of ATTR variants in Italy’ Open
v
View article: Predictors of disease burden in patients with untreated transthyretin amyloid cardiomyopathy and their caregivers: a post hoc analysis of an international survey
Predictors of disease burden in patients with untreated transthyretin amyloid cardiomyopathy and their caregivers: a post hoc analysis of an international survey Open
Introduction Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive condition with debilitating symptoms. The self-reported burden of ATTR-CM on patients and their caregivers was previously evaluated in an international, multicent…
View article: Diagnostic Accuracy of Bisphosphonate Scintigraphy in Glu54GlnATTR Cardiomyopathy
Diagnostic Accuracy of Bisphosphonate Scintigraphy in Glu54GlnATTR Cardiomyopathy Open
Background: Bisphosphonate scintigraphy (BS) is a recognized tool for diagnosing amyloid transthyretin cardiomyopathy (ATTR-CA). However, its sensitivity for rare transthyretin (TTR) variants, like Glu54Gln, remains underexplored. Methods:…
View article: The American College of Cardology/American Heart Association Heart Failure Staging System Highlights Diagnostic Delay and Predicts Outcome in Transthyretin Cardiac Amyloidosis
The American College of Cardology/American Heart Association Heart Failure Staging System Highlights Diagnostic Delay and Predicts Outcome in Transthyretin Cardiac Amyloidosis Open
View article: Evolution of Cardiac Damage Staged With Echocardiography in Fabry Disease
Evolution of Cardiac Damage Staged With Echocardiography in Fabry Disease Open
Background Fabry disease can be classified in 4 stages based on the extent of cardiac damage assessed with echocardiography. This staging is strongly associated with prognosis, with a doubled risk increase of cardiovascular events for each…
View article: High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy
High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy Open
BACKGROUND: Thresholds to define prognosis with hs-cTnI (high-sensitivity cardiac troponin I) have not been systematically addressed in wild-type transthyretin amyloid cardiomyopathy, in part because of the multiplicity of hs-cTnI assays. …
View article: Echocardiographic Tissue Characterization Using Radiomics in Patients With Transthyretin-Related Cardiac Amyloidosis
Echocardiographic Tissue Characterization Using Radiomics in Patients With Transthyretin-Related Cardiac Amyloidosis Open
View article: Frailty, disability, and malnutrition assessment for preventive measure in transthyretin cardiac amyloidosis
Frailty, disability, and malnutrition assessment for preventive measure in transthyretin cardiac amyloidosis Open
Background The prevalence of transthyretin cardiac amyloidosis (ATTR-CA) among older adults is increasing. Whether age and geriatric syndromes bear any impact on the management and outcomes in ATTR-CA is poorly understood. Methods In a pro…
View article: Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy Open
View article: Genotype-Negative Patients With Familial Hypertrophic Cardiomyopathy
Genotype-Negative Patients With Familial Hypertrophic Cardiomyopathy Open
View article: Central venous oxygen saturation as an early marker of systemic inflammatory response syndrome and predictor of outcome in cardiogenic shock
Central venous oxygen saturation as an early marker of systemic inflammatory response syndrome and predictor of outcome in cardiogenic shock Open
Background Patients with cardiogenic shock (CS) can develop systemic inflammatory response because of the cytokine storm, particularly those with higher SCAI stage. Central and mixed oxygen venous saturation (SvO2/ScvO2), are early markers…
View article: Clinical Phenotype and Prognostic Significance of Frailty in Transthyretin Cardiac Amyloidosis
Clinical Phenotype and Prognostic Significance of Frailty in Transthyretin Cardiac Amyloidosis Open
Frailty is common in ATTR-CA and is independently linked to increased mortality risk. Incorporating frailty assessment alongside traditional markers enhances prognostication across genotypes and disease severities, particularly for short-t…
View article: Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy Open
View article: Managing Complex Coronary Revascularization of Acute Coronary Syndrome During Cogan Syndrome
Managing Complex Coronary Revascularization of Acute Coronary Syndrome During Cogan Syndrome Open